[
  {
    "ts": null,
    "headline": "FDA approved AI device that predicts cancer prognosis",
    "summary": "The ArteraAI prostate test uses artificial intelligence and biomarkers to predict if standard hormone therapy will be effective and for how long.",
    "url": "https://finnhub.io/api/news?id=8a1d3087a2a07b626010064cadc612315fefb2fe10ffc284864907bfd06c22b1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755187292,
      "headline": "FDA approved AI device that predicts cancer prognosis",
      "id": 136408327,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The ArteraAI prostate test uses artificial intelligence and biomarkers to predict if standard hormone therapy will be effective and for how long.",
      "url": "https://finnhub.io/api/news?id=8a1d3087a2a07b626010064cadc612315fefb2fe10ffc284864907bfd06c22b1"
    }
  },
  {
    "ts": null,
    "headline": "Back To Basics: Why I Favor Amgen Over Johnson & Johnson",
    "summary": "Amgen (AMGN) and Johnson & Johnson (JNJ) recently received a 60-day ultimatum to lower prices in the U.S. market. A fundamental analysis shows AMGN to be better positioned. Read more here.",
    "url": "https://finnhub.io/api/news?id=b05d8175133f66cab3c53b74e587259f1ca29ba6b210173f4902d37e435e0b01",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755184015,
      "headline": "Back To Basics: Why I Favor Amgen Over Johnson & Johnson",
      "id": 136350990,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2161348037/image_2161348037.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Amgen (AMGN) and Johnson & Johnson (JNJ) recently received a 60-day ultimatum to lower prices in the U.S. market. A fundamental analysis shows AMGN to be better positioned. Read more here.",
      "url": "https://finnhub.io/api/news?id=b05d8175133f66cab3c53b74e587259f1ca29ba6b210173f4902d37e435e0b01"
    }
  },
  {
    "ts": null,
    "headline": "BNY Mellon Dynamic Value Fund Q2 2025 Commentary",
    "summary": "BNY Mellon Dynamic Value Fund (Class A at NAV) returned 5.00% during the second quarter of 2025. Read more here.",
    "url": "https://finnhub.io/api/news?id=f892debf18bb28d5f4de92b2de0ead36e77ceb9bc730d5f77257082a710ef40e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755172800,
      "headline": "BNY Mellon Dynamic Value Fund Q2 2025 Commentary",
      "id": 136348578,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1344940351/image_1344940351.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "BNY Mellon Dynamic Value Fund (Class A at NAV) returned 5.00% during the second quarter of 2025. Read more here.",
      "url": "https://finnhub.io/api/news?id=f892debf18bb28d5f4de92b2de0ead36e77ceb9bc730d5f77257082a710ef40e"
    }
  }
]